Journal of Hepatology

Article	Citations
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement	2004
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update	1398
The gut-liver axis in liver disease: Pathophysiological basis for therapy	879
Baveno VII – Renewing consensus in portal hypertension	815
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update	646
COVID-19: Abnormal liver function tests	639
EASL recommendations on treatment of hepatitis C: Final update of the series☆	618
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma	525
SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19	431
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study	399
Global burden of primary liver cancer in 2020 and predictions to 2040	368
COVID-19 and the liver	348
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study	345
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis	302
COVID-19: Discovery, diagnostics and drug development	281
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials	280
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients	274
The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology	273
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆	266
High rates of 30-day mortality in patients with cirrhosis and COVID-19	254
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis	254
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma	253
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma	245
NAFLD as a driver of chronic kidney disease	241
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients	241

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials	229
Update on NAFLD genetics: From new variants to the clinic	222
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States	217
Molecular targeted therapies: Ready for “prime time” in biliary tract cancer	215
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF	215
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy	209
Systemic treatment of hepatocellular carcinoma: An EASL position paper	202
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry	198
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	197
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡	191
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis	190
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	185
Impact of COVID-19 on global HCV elimination efforts	175
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients	165
Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis	164
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma	161
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis	159
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?	156
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis	154
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis	152
Epidemiology and risk-stratification of NAFLD-associated HCC	149
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis	148
Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology	147
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆	146
Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis	145
The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care	142
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis	141
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy	139
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study	137
Sarcopenia and frailty in decompensated cirrhosis	136
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis	135
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction	135
Animal models for liver disease – A practical approach for translational research	135
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis	132
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma	128
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping	126
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits	124
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score	122
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases	121
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals	121
Global burden of liver disease: 2023 update	121
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort	120
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis	117
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation	113
The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease	113
Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma	112
A new perspective on NAFLD: Focusing on lipid droplets	111
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy	110
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma	110
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options	110

Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”	110
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry	109
Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial	109
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease	108
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis	107
Lytic cell death in metabolic liver disease	107
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma	107
A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis	107
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis	106
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease	105
Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance	105
IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease	105
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis	105
Innate immune cells in cirrhosis	104
Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation	104
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?	103
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension	102
Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice	102
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription	102
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial	101
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS	101
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension	101
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	100
The microbiota in cirrhosis and its role in hepatic decompensation	100
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis	100
Association of liver abnormalities with in-hospital mortality in patients with COVID-19	99
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	99
Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view	97
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma	97
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma	96
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis	96
Alternatively activated macrophages promote resolution of necrosis following acute liver injury	95
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	95
Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis	93
Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure	91
COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma	90
Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival	90
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)	89
Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies	89
Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease	89
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial	88
Current knowledge and management of portal vein thrombosis in cirrhosis	88
Combined hepatocellular-cholangiocarcinoma: An update	88
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy	88
MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis	87
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality	87
The changing context of hepatitis D	86
Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019	85
SARS-CoV-2 infection in patients with autoimmune hepatitis	84
HCC surveillance after SVR in patients with F3/F4 fibrosis	83
Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development	83
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort	82
Epitranscriptomics in liver disease: Basic concepts and therapeutic potential	82
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease	81
Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound	81
Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study	80
Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis	80
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta	78
Changes in frailty are associated with waitlist mortality in patients with cirrhosis	78
Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling	77
Portopulmonary hypertension in the current era of pulmonary hypertension management	77
Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis	76
Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis	76
Impact of non-invasive biomarkers on hepatology practice: Past, present and future	75
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial	75
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism	75
Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure	75
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease	74
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA	74
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis	73
EASL Clinical Practice Guidelines on sclerosing cholangitis	73
Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B	73
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD	73
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial	73
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B	72
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma	72
Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: Reversed by anti-TNF-α treatment	72
Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx	71
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma	71
The mRNA COVID-19 vaccine – A rare trigger of autoimmune hepatitis?	71

Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure	71
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis	70
Systemic treatment of HCC in special populations	70
Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival	70
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications	69
NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly	69
Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors	69
Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?	69
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry	69
Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality	69
Hepatokines and adipokines in NASH-related hepatocellular carcinoma	68
Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma	68
Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury	68
Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes	68
Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity	67
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity	67
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?	66
Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model	66
Breakthroughs in therapies for NASH and remaining challenges	66
Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis	65
Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?	65
Mitochondrial alterations in fatty liver diseases	65
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis	64
Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]	64
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease	64
Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease	64
Towards a new definition of decompensated cirrhosis	64
The fecal mycobiome in non-alcoholic fatty liver disease	64
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B	64
Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease	64
Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy	64
ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development	64
Liver injury following SARS-CoV-2 vaccination: A multicenter case series	62
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study	62
Hepatic benefits of HCV cure	62
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study)	62
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease	62
Management of bacterial and fungal infections in cirrhosis: The MDRO challenge	62
Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications	61
A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma	61
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis	61
Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer	61
Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events	61
Cell therapy for advanced liver diseases: Repair or rebuild	60
Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection	60
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis	59
CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection	59
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs	59
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis	59
Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication	58
Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH	58
Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis	58
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma	57
Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections	57
Genotype correlates with the natural history of severe bile salt export pump deficiency	57
Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B	57
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH	57
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group	57
Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990–2019	57
NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues	57
Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe	57
Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p	57
HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure	57
Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma	56
DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer	56
Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load	56
Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis	56
Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults	56
Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs	56
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma	56
Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD	55
Asian perspective on NAFLD-associated HCC	55
Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study	55
Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma	55
Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality	54
Diagnosis and management of secondary causes of steatohepatitis	54
Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies	54
Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation	54
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum	53
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes	53
48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection	53
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease	53
Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites	53
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease	52
MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways	52
A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA	52
Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients	52
Treatment failure with DAA therapy: Importance of resistance	52
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention	52
Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis	52
Acute-on-chronic liver failure: A distinct clinical syndrome	51
Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure	51
Bile formation and secretion: An update	51
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels	51
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group	51